ABSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Absci Corp (ABSI) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock's weak financial performance, lack of clear positive catalysts, and bearish sentiment from hedge funds and analysts suggest limited upside potential in the near term. While there is some technical stability, the absence of strong trading signals and the company's high-risk profile make it better suited for monitoring rather than immediate investment.
The MACD is slightly positive at 0.0488, indicating weak bullish momentum, but it is contracting. RSI at 53.159 is neutral, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price direction. Key support is at 2.449, and resistance is at 3.129, indicating a narrow trading range.
ABS-201 has entered clinical trials with promising preliminary safety data, which could lead to future developments.
Hedge funds are selling heavily, with a 1029.38% increase in selling activity. Analysts have downgraded the stock and reduced price targets due to increased risk and reduced visibility of near-term execution. The company reported weak Q4 financials with declining revenue and increasing R&D expenses.
In Q4 2025, revenue dropped to $650,000, down -2.26% YoY. Net income was -$29.56M, a slight improvement of 2% YoY. EPS fell to -0.2, down -20% YoY. Gross margin remained at 100%, but the overall financial performance highlights significant losses and limited growth.
Morgan Stanley downgraded the stock to Equal Weight from Overweight and reduced the price target to $4.20 from $4.32, citing increased risk and reduced visibility of near-term execution.
